Glucosamine Plus Extra Strength 90c by Douglas Laboratories
Douglas Laboratories' Glucosamine Plus Extra Strength capsules offer a unique combination of glucosamine sulfate and chondroitin sulfate, two key ingredients for maintaining healthy connective tissues. Glucosamine sulfate is an essential precursor in the formation of connective tissues, while chondroitin sulfate helps to support the same. The product is sodium-free, as it utilizes a potassium-stabilized form of glucosamine sulfate. This supplement may be beneficial for those looking to support connective tissues, such as skin, tendons, ligaments, bone, and cartilage. It may also help to address symptoms associated with weakened connective tissues, such as joint pain, stiffness, and swelling. The combination of glucosamine sulfate and chondroitin sulfate makes this product unique in the marketplace, as these ingredients are rarely found in the same supplement. By taking Glucosamine Plus Extra Strength capsules, individuals may be able to support their connective tissues and experience relief from symptoms associated with weakened connective tissues. It is important to note that this product has not been evaluated by the FDA and no claims may be made regarding its efficacy.Recommendation:
Douglas Labs suggests, as a dietary supplement, adults take one vegetarian capsule up to three times daily or as directed by a healthcare professional.
Serving Size: 1 Vegetarian Capsule
Servings Per Container: 90
Amount Per Serving:
Glucosamine Sulfate (from crab and shrimp) 500 mg
Chondroitin sulfate 400 mg
Other ingredients: Hydroxypropyl methylcellulose (capsule) and vegetable stearate.
Contains: Shellfish (crab, shrimp)
STORAGE
Store in a cool, dry place, away from direct light. Keep out of reach of children.
Warning: If you have an allergy to shellfish, (including crab and shrimp) you should not use this product.
Douglas Laboratories logo, text, graphics, and photo images are the property of Société des Produits Nestlé S.A. and are used with permission. Copyright © 2021.